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Abstract
We report a rare case of association of temporal arteritis with recurrent central corneal ulcer. A
91-year-old male with a remote history of clinically diagnosed giant cell arteritis (GCA) and penetrating keratoplasty (PK) for corneal edema in 1990’s in the left eye presented with irritation and
severe dry eye. He progressively developed central corneal ulcer regardless of treatment with aggressive lubrication and patching. The clinical course, blood tests and temporal artery biopsy results yielded the diagnosis of recurrent GCA. The clinical course improved after starting oral steroids. The case report illustrates the importance of ruling out GCA in patients with recurrent corneal ulcers and history of GCA. It also highlights the significance of shared understanding between
primary care physicians and specialists to handle common and chronic diseases to make efficient
diagnoses and plan treatment regimens. This is the first plausible case of reported GCA association
with central corneal ulcer in the United States.
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1. Introduction
Giant cell arteritis is a vasculitis of medium and large size arteries, predominantly involving the carotid artery
system extending to the temporal artery and branches of the ophthalmic artery. In individuals aged 50 years or
older, the average incidence was 18.3 per 100,000 inhabitants with 25 for women and 9.3 for men [1]. The classic symptoms include headache, scalp tenderness, tongue and jaw claudication, and loss of vision. Nonspecific
constitutional symptoms such as fever and weight loss are also often reported. Polymyalgia rheumatic (PR)
*

Corresponding author.

How to cite this paper: Bondalapati, S., Khine, K., Bitar, M., Chesnutt, D. and Davis, R.M. (2016) A Rare Association of Giant
Cell Arteritis with Recurrent Corneal Ulcer. Open Journal of Ophthalmology, 6, 144-149.
http://dx.doi.org/10.4236/ojoph.2016.63020

S. Bondalapati et al.

symptoms such as tenderness and pain in the shoulder need attention as these are observed in 50% of the cases
with biopsy proven GCA [2] [3].
Most common signs are vision loss, thickened, dilated and occasionally erythematous temporal artery with
reduced or absent pulse, and tender palpable nodules [2]. The frequency of the other ocular manifestations in
GCA isreported as 12.2% central retinal artery occlusion (CRAO), 21.2% cilioretinal artery occlusion, 76.4%
anterior ischemic optic neuropathy (AION), 5.7% posterior ischemic optic neuropathy, 31% amaurosisfugax, 6%
diplopia, and rarely anterior segment ischemia [4]. Previously in literature, the presentation of GCA with unusual anterior segment signs, such as limbal guttering [5], scleritis [6], corneal edema [7] and peripheral ulcerative keratitis (PUK) [8], have been reported but not recurrent central corneal ulcer. We document here such a
case in a patient with GCA.

2. Case Report
A 91-year-old Caucasian male with ocular history of primary open angle glaucomain the right eye (OD), mixed
mechanism glaucoma in the left eye (OS) and dry eye in both eyes(OU), presented with severe irritation OS. He
had a past ocular surgical history of cataract extraction OU and corneal transplantation OS more than twenty
years ago for corneal edema. Of note, he had a history of non-biopsy proven GCA, which was diagnosed a decade ago based on symptoms. He was treated at that time with a short course of prednisone. Other medical and
surgical history included hypertension controlled on medication, osteoarthritis, prostate cancer under treatment
with androgen deprivation therapy, and knee replacement surgery. His current ocular medications consisted of
dorzolamide/timolol for glaucoma and artificial tears for dry eyes.
At this visit, best corrected visual acuity (BCVA) was 20/50 and 20/200 with intraocular pressures (IOP) of
20 mmHg and 11 mmHg in the OD and OS respectively. Slit lamp exam (SLE) showed no lagophthalmos and
normal conjunctiva with good tear lakes OU. The cornea OD had some superficial punctate epitheliopathy
(SPE). The graft OS had a 6 mm × 5 mm paracentral epithelial defect involving stroma with adjacent peripheral
neovascularization butno infiltrate. The rest of the exam was unremarkable with deep and quiet anterior chamber,
round iris and posterior chamber intraocular lens in good position OU. Fundus exam revealed cup to disc of 0.85
OD and 0.8 with superior thinning in the OS otherwise unremarkable posterior segment exam OU. The patient
was treated with aggressive lubrication followed by eyelid patching for a few days. Epithelial defect improved
but irritation worsened.
At the four-week follow-up, the patient reported pain in the left eye and left temple. Vision had deteriorated to
hand motion OS. Examination revealed a hazy corneal graft OS with a descemetocele. Cyanoacrylate glue was
used to stabilize the cornea and a contact lens was placed to prevent corneal perforation. Given the history of
GCA, ESR was ordered and was found to be 65 mm/h. The patient was diagnosed with recurrence of GCA and
treated with 40 mg oral prednisone by his primary care physician (PCP). At one-month follow-up, prednisone
was tapered to 10 mg maintenance dose as patient had clinically improved with visual acuity 20/400. On exam,
the central cornea was 90% epithelialized with a small residual epithelial defect inferonasally with, persistent
haze and neovascularization shown in Figure 1.

(a)

(b)

Figure 1. Slit lamp images of left eye at the time of the first ulcer episode showing (a) Corneal neovascularization from 7’o clock to 9’o clock position and inferonasal ulcer encroaching visual axis. (b)
Persistent epithelial defect enhanced with fluorescein stain.
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A year later, patient was doing well with no epithelial defect and was still treated with 10 mg maintenance
dose steroids. However, there was persistent haze and neovascularization OS necessitating repeat penetrating
keratoplasty (PK). The surgical pathology specimen had moderate loss of endothelium and focal scarring. At
one-month follow-up, the graft was still very edematous with neovascularization. As a result of this graft failure,
the patient underwent repeat PK. His BCVA improved to 20/40 OS. Six months after repeat PK, his new PCP
was concerned about worsening osteoporosis from chronic steroid use and decided to discontinue prednisone
treatment. The PCP ordered ESR and CRP. The results were within normal lab reference range (8 mm/hr and 0.6
mg/L respectively) and prednisone was tapered. Two weeks after stopping steroids, patient presented with worsening left eye irritation. On examination, BCVA was 20/200 OS with diffuse SPE in the graft. He was treated
for dry eyes with aggressive gel lubrication. Four-week slater, patient came in complaining persistent left eye irritation with left scalp tenderness and fatigue. Visual acuity was stable at 20/200 OS. Examination revealed a
central corneal epithelial defect with stromal thinning but no infiltrate, no neovascularization and noanterior
chamber inflammation. A soft contact lens was placed for two days, which did not resolve the central ulcer.
Hence, contact lens was removed and the eye was patched for 48 hours. Patient was restarted on oral prednisone
at a dose of 20 mg and it was increased to 40 mg a few days later because of lack of improvement. At one-week
follow-up, the left cornea had developed a descemetocele necessitating placement of cyanoacrylate glue and a
contact lens as seen in Figure 2.
Laboratory testing was performed. ESR and CRP were within the normal reference. Anti-nuclear antibody
(ANA)was positive with speckled pattern and a titer of 1:160. Speckled pattern is associated with many conditions including lupus, Sjogren’s, mixed connective tissue disease, scleroderma, and polymyositis/dermatomyositis but not specific to any autoimmune disease. In our patient, Extractable nuclear antigen (ENA), which is a
marker for above immune disorders, was negative. Since the suspicion for recurrent GCA was high, temporal
artery biopsy (TAB) was performed. The result revealed focal peri-internal elastica fibrosis including foci of
medial fibrosis supporting diagnosis of healed arteritisas perceived in Figure 3. In the next four weeks, symptoms improved, visual acuity was count fingers at one foot and the ulcer consolidated. Findings were communicated to the PCP who then agreed to continue the steroid treatment. Prednisone was tapered to a 20 mg maintenance dose. At eight-week follow-up, the contact lens and glue were in place, graft was clear peripherally with
neovascularization at 9, 10 and 11’0 clock positions and visual acuity was stable but the eye was still tender to
touch. Prednisone was increased to 30 mg with plan for slow taper in the future. At eleven-week follow-up with
neuro-ophthalmology, patient reported taking 15 mg prednisone daily and that his headaches had stopped. Visual acuity was unchanged with normal IOP in the OS.

3. Discussion
The clinical criteria established by the American College of Rheumatology (ACR) for diagnosis of GCA is: 1)
age ≥ 50 years, 2) new onset localized headaches, 3) temporal artery tenderness or decreased temporal artery
pulse, 4) ESR ≥ 50 mm/h and 5) superficial TAB consistent with GCA [9]. The presence of three of the five criteria was calculated to yield a 93.5% sensitivity and 91.2% specificity [9]. However, Murchisen et al. found that

Figure 2. Left eye after the repeat corneal transplant; at
two-week follow-up after sealing the ulcer with cyanoacrylate glue and contact lens placement.
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Figure 3. (a) The von geison stain (black) highlights focal disruptions in the internal elastic lamina; (b) The trichrome stain
(blue) shows mild focal fibrosis (arrow) in the tunica media.

the use of ACR criteria alone could miss up to 25% of GCA diagnosis [10] [11]. Hayreh et al. also reviewed
ACR guidelines and reflected that it did not include other important clinical criteria such as jaw claudication,
neck pain and therefore suggested revision [4]. Blood tests for ESR and CRP are highly useful in the diagnosis
of GCA, although neither of them is 100% sensitive and specific but together provides the best specificity of 97%
[4]. Hence, Hayreh et al. recommended using both ESR and CRP for diagnosis and management of GCA [4].
Biopsy of the temporal artery is the gold standard for diagnosis of GCA. Initiation of high dose steroid treatment
before confirming the diagnosis is warranted to protect the residual vision in the affected eye and the fellow eye.
GCA patients usually need steroid treatment for much longer than two years with median lowest dose of 7
mg/day (range 1 - 16 mg/day) [4]. To maintain the lowest levels of ESR and CRP and to keep GCA under control, most patients require a small maintenance dose indefinitely for variable duration [4].
In our patient, the signs and symptoms were atypical and recurrence of GCA was unusual after a decade. He
presented with recurrent central corneal melting, mild tenderness of temporal arteries and hip pain but denied
other GCA associated symptoms. His ESR and CRP were normal but they were tested a couple days after restarting the steroid which may have affected the result. Negative ENA rendered other autoimmune diseases
known to be associated with recurrent corneal melting like SLE and Sjogren’s less likely. The absence of symmetric and small joint pains ruled out rheumatoid arthritis. Positive TAB confirmed the diagnosis of recurrent
GCA. Alba et al. reported 36% relapse of GCA in two or more years in a cohort study that followed patients for
7.8 ± 3.3 years [12]. The longest time for relapse reported in the literature was 21 years after initial diagnosis
and presented with an unusual sign of leg ulcer [13]. Vague symptoms and atypical signs of GCA at relapse can
mislead physicians, especially if the history of GCA is remote and no clear records are available. This may delay
the diagnosis and proper treatment. Increased awareness is required for prompt recognition of this potentially
devastating disease because transient monocular vision loss may be a warning symptom before permanent vision
loss occurs.
In our patient, the mechanism of corneal ulcer is unclear. It could be due to hypoxia secondary to ischemia of
the limbal circulation from vasculitis. Subclinical autoimmune disease with positive ANA could also be causing
deposition of immune complexes in the cornea. Affected epithelium, keratocytes, and recruited inflammatory
cells might be releasing matrix metalloproteinases (MMP), which would degrade collagen and the extracellular
matrix. It is also possible that autoantibodies target corneal epithelium as hypothesized in peripheral ulcerative
keratitis [14] although the ulcer was more central in our case. Avascular cornea can limit the efficiency of effector cell recruitment although neutrophils, monocytes and lymphocytes can readily migrate through stroma
when appropriate chemotactic stimuli are activated [15].
This case report reiterates that integrated clinical care plays a vital role in the successful management of patients’ health as stopping the prednisone precipitated the recurrence of the corneal ulcer. Effective communication between primary care physicians and specialists regarding patient referrals and consultations is necessary
for coordinated care and it improves patient outcomes and physician satisfaction [16].
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To our knowledge, this is the first case report which illustrates a rare association of central corneal ulcer with
GCA. Early recognition of such rare associations is important for prompt treatment and good visual outcome of
the patients.
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Abbreviation List
GCA—Giant Cell Arteritis
PK—Penetrating Keratoplasty
PR—Polymyalgia Rheumatica
CRAO—Central Retinal Artery Occlusion
AION—Anterior Ischemic Optic Neuropathy
PUK—Peripheral Ulcerative Keratitis
OD—Right Eye
OS—Left Eye
BCVA—Best Corrected Visual Acuity
IOP—Intraocular Pressure
SLE—Slit Lamp Exam
SPE—Superficial Punctate Epitheliopathy
ESR—Erythrocyte Sedimentation Rate
CRP—C-Reactive Protein
PCP—Primary Care Physician
ANA—Anti-Nuclear Antibody
ENA—Extractable Nuclear Antigen
ACR—American College of Rheumatology
TAB—Temporal Artery Biopsy
MMP—Matrix Metalloproteinases
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